首页|COPD合并肺源性心脏病患者血清ICOS、ICOSL水平变化及临床意义

COPD合并肺源性心脏病患者血清ICOS、ICOSL水平变化及临床意义

Changes in serum ICOS and ICOSL levels and clinical significance in patients with COPD combined with pulmonary heart disease

扫码查看
目的 观察慢性阻塞性肺疾病(COPD)合并肺源性心脏病(PHD)患者血清诱导性共刺激分子(ICOS)和诱导性共刺激分子配体(ICOSL)水平变化及临床意义.方法 选择2020 年6 月—2023 年2 月上海交通大学医学院苏州九龙医院心内科收治COPD患者172 例,根据患者是否合并PHD分为合并PHD组82 例和COPD组90例.根据肺动脉收缩压(PASP)将PHD患者分为轻度亚组(30~50 mmHg,21 例)、中度亚组(51~70 mmHg,37 例)和重度亚组(≥71 mmHg,24 例),再根据纽约心脏病协会(NYHA)分级将PHD患者分为Ⅰ~Ⅱ级亚组(44 例)、Ⅲ~Ⅳ级亚组(38 例).酶联免疫吸附试验检测血清ICOS、ICOSL水平,分析ICOS、ICOSL与PASP、NYHA分级之间的相关性,受试者工作特征(ROC)曲线分析 ICOS、ICOSL 诊断 COPD 合并 PHD 的价值.结果 合并 PHD 组血清 ICOS、ICOSL水平高于COPD组(t =14.526、34.508,P均<0.001).重度亚组血清ICOS、ICOSL及PASP水平高于中度亚组和轻度亚组(F/P =125.351/<0.001、163.591/<0.001、84.292/<0.001),Ⅲ~Ⅳ级亚组血清ICOS、ICOSL水平均高于Ⅰ~Ⅱ级亚组(t/P =11.658/<0.001、27.345/<0.001).PHD患者血清ICOS、ICOSL水平与PASP、NYHA分级均呈正相关(r =0.439、0.416、0.501、0.497,P均<0.001).血清ICOS、ICOSL及二者诊断COPD患者合并PHD的曲线下面积分别为0.780、0.723、0.926,二者联合高于单独ICOS、ICOSL诊断(Z =4.021、5.194,P均<0.001).结论 COPD合并PHD患者血清ICOS、ICOSL水平显著增高,且与肺动脉高压以及心功能降低有关,联合检测ICOS、ICOSL可有效评估COPD患者PHD风险.
Objective To observe the changes of serum levels of inducible co-stimulatory molecules(ICOS)and inducible co-stimulatory molecule ligands(ICOSL)and clinical significance in patients with chronic obstructive pulmonary disease(COPD)combined with pulmonary heart disease(PHD).Methods One hundred and seventy-two COPD patients admitted to the Department of Cardiology,Suzhou Jiulong Hospital,School of Medicine,Shanghai Jiaotong University,from June 2020 to February 2023 were selected and divided into the PHD group(82 patients)and the COPD group(90 patients)according to whether they were combined with PHD or not.PHD patients were divided into mild subgroups(30-50 mmHg,21 cases),moderate subgroups(51-70 mmHg,37 cases),and severe subgroups(≥71 mmHg,24 cases)according to pulmo-nary artery systolic pressure(PASP),and then PHD patients were divided into subgroups of grades ⅠtoⅡ(44 cases),and grades Ⅲ to Ⅳ(38 cases)according to the New York Heart Association(NYHA)classification.Enzyme-linked immunosor-bent assay(ELISA)was used to detect serum ICOS and ICOSL levels and analyze the correlation between ICOS,ICOSL and PASP,NYHA classification,and the value of ICOS and ICOSL in diagnosing COPD combined with PHD was analyzed by the subject's work characteristics(ROC)curve.Results The serum ICOS and ICOSL levels in the PHD group were higher than those in the COPD group(t=14.526,34.508,P<0.001).Serum ICOS and ICOSL levels were higher in the severe sub-group than in the moderate and mild subgroups(F/P=125.351/<0.001,163.591/<0.001,84.292/<0.001),and serum ICOS was higher in the subgroups of grade III-IV,ICOSL levels were higher than those in the subgroups of grades I-II(t/P= 11.658/<0.001,27.345/<0.001).The serum ICOS and ICOSL levels of patients with PHD were positively correlated with the PASP and NYHA grading(r=0.439,20.416,0.501,0.497,P<0.001).ICOS,ICOSL and both the area under the curve of com-bined PHD in patients with COPD diagnosis was 0.780,0.723,0.926,respectively,and the combination of the two was higher than the diagnosis of ICOS and ICOSL alone(Z=4.021,5.194,and Pall<0.001).Conclusion Serum ICOS and ICOSLlevels were significantly higher in patients with COPD combined with PHD,and were associated with pulmonary hypertension and reduced cardiac function,and the combined detection of ICOS and ICOSL could effectively evaluate the risk of PHD in pa-tients with COPD.

Chronic obstructive pulmonary diseasePulmonogenic heartPulmonary hypertensionInducible co-stimulatory moleculesInducible co-stimulatory molecular ligands

钱王燕、虞鸣娟、陈访、李妍妍、张赛、葛小宁、陈润祥

展开 >

215000 上海交通大学医学院苏州九龙医院检验科

215000 上海交通大学医学院苏州九龙医院心内科

慢性阻塞性肺疾病 肺源性心脏病 肺动脉高压 诱导性共刺激分子 诱导性共刺激分子配体

江苏省卫生健康委科研项目

BJ22074

2024

疑难病杂志
中国医师协会

疑难病杂志

CSTPCD
影响因子:1.171
ISSN:1671-6450
年,卷(期):2024.23(3)
  • 21